ORCHPHARMA

Orchid Pharma Share Price

 

 

Start SIP in ORCHPHARMA

Start SIP

Performance

  • Low
  • ₹850
  • High
  • ₹876
  • 52 Week Low
  • ₹604
  • 52 Week High
  • ₹1,997
  • Open Price₹867
  • Previous Close₹865
  • Volume52,567

Investment Returns

  • Over 1 Month + 4.57%
  • Over 3 Month + 21.74%
  • Over 6 Month + 20.82%
  • Over 1 Year -50.54%

Smart Investing Starts Here Start SIP with Orchid Pharma for Steady Growth!

Invest Now

Orchid Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 84.2
  • PEG Ratio
  • -1.5
  • Market Cap Cr
  • 4,401
  • P/B Ratio
  • Average True Range
  • 36.26
  • EPS
  • 10.3
  • Dividend Yield
  • 0
  • MACD Signal
  • 25.16
  • RSI
  • 61.53
  • MFI
  • 64.6

Orchid Pharma Financials

Orchid Pharma Technicals

EMA & SMA

Current Price
₹867.70
+ 2.55 (0.29%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹837.58
  • 50 Day
  • ₹799.74
  • 100 Day
  • ₹790.09
  • 200 Day
  • ₹851.65

Resistance and Support

864.47 Pivot Speed
  • R3 904.63
  • R2 890.17
  • R1 878.93
  • S1 853.23
  • S2 838.77
  • S3 827.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and central nervous system therapies.

Orchid Pharma has an operating revenue of Rs. 821.27 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 10% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 11% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 10 which is a POOR score indicating inconsistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Orchid Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-12 Quarterly Results
2025-05-26 Audited Results
2025-02-12 Quarterly Results
2024-11-11 Quarterly Results

Orchid Pharma F&O

Orchid Pharma Shareholding Pattern

69.84%
18.04%
0.14%
1.56%
0.06%
7.03%
3.33%

About Orchid Pharma

  • NSE Symbol
  • ORCHPHARMA
  • BSE Symbol
  • 524372
  • Managing Director
  • Mr. Manish Dhanuka
  • ISIN
  • INE191A01027

Similar Stocks to Orchid Pharma

Orchid Pharma FAQs

Orchid Pharma share price is ₹867 As on 07 December, 2025 | 17:26

The Market Cap of Orchid Pharma is ₹4400.9 Cr As on 07 December, 2025 | 17:26

The P/E ratio of Orchid Pharma is 84.2 As on 07 December, 2025 | 17:26

The PB ratio of Orchid Pharma is 3.6 As on 07 December, 2025 | 17:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23